Hims & Hers Health (NYSE:HIMS) Given New $39.00 Price Target at Truist Financial

Hims & Hers Health (NYSE:HIMS) had its price objective raised by Truist Financial from $24.00 to $39.00 in a research note released on Wednesday morning,Benzinga reports. Truist Financial currently has a hold rating on the stock.

HIMS has been the subject of a number of other research reports. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. TD Cowen reaffirmed a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday. Citigroup raised their price target on Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a research note on Tuesday. Finally, Needham & Company LLC upped their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $34.47.

Hims & Hers Health Stock Up 5.0 %

NYSE:HIMS opened at $41.87 on Wednesday. The firm’s fifty day simple moving average is $35.89 and its 200 day simple moving average is $26.36. The stock has a market cap of $9.15 billion, a P/E ratio of 95.15 and a beta of 1.35. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 33,513 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $1,118,296.76. This trade represents a 50.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,097,578 shares of company stock worth $38,080,320 in the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $200,000. Mackenzie Financial Corp raised its holdings in Hims & Hers Health by 44.6% in the 4th quarter. Mackenzie Financial Corp now owns 29,096 shares of the company’s stock valued at $704,000 after acquiring an additional 8,977 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $99,000. Neo Ivy Capital Management lifted its stake in Hims & Hers Health by 145.4% in the 4th quarter. Neo Ivy Capital Management now owns 166,734 shares of the company’s stock worth $4,031,000 after purchasing an additional 98,798 shares in the last quarter. Finally, PharVision Advisers LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $234,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.